Back to search

Article

Single-cell repertoire tracing identifies rituximab refractory B cells during myasthenia gravis relapses

2019-11-14

Abstract excerpt

Rituximab, a B cell-depleting therapy, is indicated for treating a growing number of autoantibody-mediated autoimmune disorders. However, relapses can occur after treatment and autoantibody-producing B cell subsets may be found during relapses. It is not understood if these autoantibody-producing B cell subsets emerge from the failed depletion of pre-existing B cells or are re-generated de novo . To further defin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
67f0983d-278c-5e0b-a227-a432ed0937ee
DOI
10.1101/840389
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Single-cell repertoire tracing identifies rituximab refractory B cells during myasthenia gravis relapsesDOI 10.1101/840389
Select a neighboring publication to make it the new centre.